carvedilol has been researched along with indomethacin in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bergström, CA; Hubatsch, I; Johansson, K; Wassvik, CM | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Sen, S; Sinha, N | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Bennis, K; Ducki, S; Lesage, F; Vivier, D | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cascone, A; Pergola, G; Russo, M | 1 |
| Grohganz, H; Jensen, KT; Kasten, G; Meng-Lund, H; Pantsar, T; Poso, A; Rades, T; Rantanen, J | 1 |
| Brede, K; Genina, N; Hempel, NJ; Knopp, MM; Löbmann, K; Olesen, NE | 1 |
| Grohganz, H; Kasten, G; Kissi, EO; Löbmann, K; Rades, T | 1 |
| Bohr, A; Grohganz, H; Löbmann, K; Mishra, J; Rades, T | 1 |
| Dunn, C; Halbert, GW; Khadra, I; Perrier, J; Wilson, CG | 1 |
| Abdel-Aziz, AM; Abdelzaher, WY; Ahmed, RF; Ibrahim, YF; Mohamed, ASM; Welson, NN | 1 |
| Arnous, A; Foderà, V; Kabedev, A; Leng, D; Löbmann, K; Sener, Z; Zhao, M; Zhuo, X | 1 |
2 review(s) available for carvedilol and indomethacin
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pain; Potassium Channels, Tandem Pore Domain; Structure-Activity Relationship | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
21 other study(ies) available for carvedilol and indomethacin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Poorly soluble marketed drugs display solvation limited solubility.
Topics: Calorimetry, Differential Scanning; Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Molecular Structure; Multivariate Analysis; Pharmaceutical Preparations; Principal Component Analysis; Solubility; Tandem Mass Spectrometry; Thermodynamics | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Acute pericarditis and myocarditis by Toxoplasma gondii in an immunocompetent young man: a case report.
Topics: Acute Disease; Adult; Aluminum Hydroxide; Antibodies, Protozoan; Carbazoles; Carvedilol; Chest Pain; Drug Therapy, Combination; Humans; Immunocompetence; Immunoglobulin G; Immunoglobulin M; Indomethacin; Magnesium Hydroxide; Male; Myocarditis; Pericarditis; Propanolamines; Spiramycin; Toxoplasma; Toxoplasmosis | 2010 |
The use of molecular descriptors in the development of co-amorphous formulations.
Topics: Amino Acids; Carbamazepine; Carbazoles; Carvedilol; Chemistry, Pharmaceutical; Discriminant Analysis; Drug Combinations; Drug Stability; Furosemide; Indomethacin; Least-Squares Analysis; Mebendazole; Models, Molecular; Pharmaceutical Preparations; Powder Diffraction; Propanolamines; Simvastatin; X-Ray Diffraction | 2018 |
A fast and reliable DSC-based method to determine the monomolecular loading capacity of drugs with good glass-forming ability in mesoporous silica.
Topics: Calorimetry, Differential Scanning; Carbazoles; Carvedilol; Cinnarizine; Drug Stability; Glass; Ibuprofen; Indomethacin; Porosity; Propanolamines; Silicon Dioxide | 2018 |
The Role of Glass Transition Temperatures in Coamorphous Drug-Amino Acid Formulations.
Topics: Amino Acids; Calorimetry, Differential Scanning; Carvedilol; Glass; Indomethacin; Transition Temperature; Tryptophan | 2018 |
Whey proteins as stabilizers in amorphous solid dispersions.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Carvedilol; Diuretics; Dosage Forms; Excipients; Furosemide; Indomethacin; Whey Proteins | 2019 |
Topography of Simulated Intestinal Equilibrium Solubility.
Topics: Acid-Base Equilibrium; Administration, Oral; Bile Acids and Salts; Body Fluids; Carvedilol; Chemistry, Pharmaceutical; Dosage Forms; Drug Liberation; Fenofibrate; Humans; Hydrogen-Ion Concentration; Indomethacin; Intestinal Absorption; Intestinal Secretions; Models, Biological; Monoglycerides; Osmolar Concentration; Phospholipids; Solubility; Surface-Active Agents | 2019 |
Potential role of carvedilol in intestinal toxicity through NF-κB/iNOS/COX-2/TNF-α inflammatory signaling pathway in rats.
Topics: Animals; Carvedilol; Cyclooxygenase 2; Indomethacin; Male; NF-kappa B; Rats; Rats, Wistar; Signal Transduction; Tumor Necrosis Factor-alpha | 2022 |
Mechanisms of Drug Solubility Enhancement Induced by β-Lactoglobulin-Based Amorphous Solid Dispersions.
Topics: Carvedilol; Celecoxib; Drug Compounding; Drug Liberation; Indomethacin; Lactoglobulins; Solubility | 2023 |